These results suggest that a complementary treatment with DHA combined with drugs targeting Ras/ERK and/or phosphoinositide signaling pathways could be particularly promising in less differentiated breast cancers overexpressing the HER2/neu receptors. Here, ERBB2 is linked to breast cancer.